Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer
BackgroundSintilimab plus chemotherapy has proven effective as a combination immunotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC). A multi-center study conducted in China revealed a median progression-free survival (PFS) of 7.1 months. However, the...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2024-05-01
|
| Serier: | Frontiers in Immunology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1407632/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
